Canadian company invests in Taiwanese biotechnology:
This article was originally published in Clinica
The Taiwanese government has entrusted $30 million of its biotechnology development fund to MDS Capital, a Canadian venture capital firm, to invest in various industry sectors, including biomedical devices, drug delivery systems and diagnostics. The move follows a recent $580 million boost from the government to help its biotech industry increase its value to $880 million by 2005 (see Clinica No 820, p 2). The company is expected to help complete ten technology transfer projects in Taiwan within the next five years.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.